Welcome to our dedicated page for Palatin Technologies news (Ticker: $PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palatin Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palatin Technologies's position in the market.
Palatin Technologies, Inc. (NYSE American: PTN) will report its third quarter fiscal year 2024 results on May 15, 2024, before the U.S. financial markets open. A conference call and webcast will follow at 11:00 a.m. ET to discuss the operating results and programs under development.
Palatin Technologies, Inc. (NYSE American: PTN) has received FDA clearance to begin a Phase 2 clinical study for the co-administration of bremelanotide with tirzepatide for treating obesity. The study is expected to start in mid-2024 with data by the end of the year. The company is hosting a virtual KOL event on May 8, 2024, to discuss its metabolic program.
Palatin Technologies, Inc. (NYSE American: PTN) will host a virtual KOL event on May 8, 2024, focusing on novel melanocortin receptor 4 agonists for treating obesity. The event will feature discussions on the current treatment landscape, the need for new treatments, and combining melanocortin agonists with incretins for optimal treatment. Palatin's Phase 2 clinical study is set to begin in mid-2024, with results expected by the end of the year.